ANIP ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Princeton, New Jersey.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About ANI Pharmaceuticals (NASDAQ: ANIP)
›
ANI Pharmaceuticals (NASDAQ: ANIP) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 970 employees.
The shares were at 69.13 USD on 19 November 2026, down 23.4% over 52 weeks. Its 52-week range is 67.14 USD to 95.45 USD: the price is 27.6% below the high and 3.0% above the low.
At a market capitalisation of 1.57B USD, it trades at 14.0 times trailing earnings and 6.8 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 43% for ANIP.
ANI Pharmaceuticals reports return on equity of 14.5%, an operating margin of 14.7% and revenue up 27.6% year over year.
Its debt exceeds its cash by 180.39M USD, a debt-to-equity ratio of 1.14. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 8 analysts cover the stock, with an average rating of Buy; their mean price target of 103.38 USD is 49.5% above the current price. The next earnings report is expected on 26 February 2027.